This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Bremelanotide activates melanocortin receptors, particularly MC4R, to potentially increase dopamine release.
Why it matters
Understanding how bremelanotide works can improve treatment options for women suffering from HSDD. This could lead to better management of female sexual dysfunction.
How the study worked
This is a review study summarizing existing research on bremelanotide's mechanism of action.
What this study cannot tell us
As a review, it summarizes existing studies but does not present new experimental data.
Read the original research
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
CNS spectrums, 27(3), 281-289
Citation
Pfaus, James G; Sadiq, Amama; Spana, Carl; Clayton, Anita H. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.. CNS spectrums, 27(3), 281-289. https://doi.org/10.1017/S109285292100002X